Fast Market Research

Valentia Biopharma S.L. - Product Pipeline Review - 2013 - New Study Released

New Pharmaceuticals market report from Global Markets Direct: "Valentia Biopharma S.L. - Product Pipeline Review - 2013"

 

Boston, MA -- (SBWIRE) -- 02/05/2014 -- Global Market Direct's pharmaceuticals report, "Valentia Biopharma S.L. - Product Pipeline Review - 2013" provides data on the Valentia Biopharma S.L.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Valentia Biopharma S.L.'s corporate website, SEC filings, investor presentations and featured press releases, both from Valentia Biopharma S.L. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Valentia Biopharma S.L. - Brief Valentia Biopharma S.L. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Valentia Biopharma S.L. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Valentia Biopharma S.L. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Valentia Biopharma S.L.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get This Report

- Evaluate Valentia Biopharma S.L.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Valentia Biopharma S.L. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Valentia Biopharma S.L.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Valentia Biopharma S.L..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Valentia Biopharma S.L. and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Array BioPharma Inc. - Product Pipeline Review - 2013
- Hemispherx Biopharma, Inc. - Product Pipeline Review - 2013
- Canopus BioPharma Incorporated - Product Pipeline Review - 2013
- Lipopharma Therapeutics SL - Product Pipeline Review - 2013
- Soricimed Biopharma Inc. - Product Pipeline Review - 2013
- Neurotec Pharma SL - Product Pipeline Review - 2013
- Lytix Biopharma AS - Product Pipeline Review - 2013
- Synageva BioPharma Corp. - Product Pipeline Review - 2013
- Alios BioPharma, Inc. - Product Pipeline Review - 2013
- Benitec Biopharma Limited - Product Pipeline Review - 2013